Close Menu

NEW YORK (GenomeWeb) – Investment bank Leerink Partners today said it has downgraded Bruker's stock to Market Perform from Outperform based on expectations that margin expansion will be more difficult than is indicated by the current stock price.

Bruker's stock has appreciated 55 percent in the past year compared to no appreciation for the S&P 500, wrote Leerink analyst Dan Leonard in his note today. Leerink believes "the large, discrete activities for margin expansion are in the rear view mirror," he added.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.